Oxigene Inc (NASDAQ:OXGN)

CAPS Rating: 3 out of 5

A biotechnology company developing novel small-molecule therapeutics to treat cancer and eye diseases.

Results 1 - 16 of 16

Recs

0
Member Avatar dcsilver (61.15) Submitted: 6/19/2014 8:11:49 AM : Outperform Start Price: $2.77 OXGN Score: -22.38

Gut feeling - following a zz play.

Recs

1
Member Avatar Crystalball (89.25) Submitted: 3/21/2014 10:32:31 AM : Outperform Start Price: $3.79 OXGN Score: -48.05

Zybrestat, when used in combination with Roche's (RHHBY) Avastin, delayed the re-growth of ovarian cancer, in recent phase II study. The potential for significant upside exists on this one, and management obvious believes in itself holding a large insider position.

Recs

0
Member Avatar BioInvestor2013 (52.64) Submitted: 3/15/2014 10:09:45 AM : Outperform Start Price: $4.22 OXGN Score: -54.89

http://bioinvestor204.blogspot.de

Recs

0
Member Avatar bcurtis9944 (27.12) Submitted: 3/12/2014 9:24:28 PM : Outperform Start Price: $4.64 OXGN Score: -58.24

An extremely high growth period for this company's stock is starting to occur. It is extremely under valued. The company's breast cancer drug has positive trials.

Recs

2
Member Avatar zzlangerhans (99.80) Submitted: 1/27/2014 6:31:51 PM : Outperform Start Price: $2.50 OXGN Score: -23.74

I couldn't let the latest biopharma massacre go by without at least one correction outperform. Oxigene is of course extremely speculative but at a fully diluted market cap of about 20M and preliminary data from the GOG 186I trial of Zybrestat for ovarian cancer expected this half this stub should stay volatile ahead of topline data release.

Recs

2
Member Avatar BACnumber1 (< 20) Submitted: 11/9/2011 4:13:45 AM : Underperform Start Price: $13.68 OXGN Score: +141.57

Sadly I own this company.....

Recs

1
Member Avatar BamaBoyT (87.29) Submitted: 9/15/2011 9:35:05 AM : Outperform Start Price: $16.44 OXGN Score: -150.27

This will be a hot stock to day trade. Will be around 5 dollars in near future.

Recs

0
Member Avatar kanol (< 20) Submitted: 5/11/2011 10:00:19 AM : Outperform Start Price: $54.34 OXGN Score: -141.29

UP UP UP EXPLOSION!

Recs

3
Member Avatar kampaakampaa (< 20) Submitted: 6/17/2010 9:51:02 AM : Underperform Start Price: $141.58 OXGN Score: +173.69

New financing and need more Falcon data

Recs

1
Member Avatar armyinu (< 20) Submitted: 6/1/2009 2:40:50 PM : Outperform Start Price: $564.00 OXGN Score: -208.86

I see it that this drud is going to finish ahead and that the FDA will aprove it and this stock is going to sky rocket if i where you I would buy buy buy

Recs

1
Member Avatar suave1007 (< 20) Submitted: 8/14/2007 6:29:40 PM : Outperform Start Price: $856.80 OXGN Score: -144.63

Science: Destroys in minutes ALL blood vessels of tumor!while preserving ALL other healthy cells!! NO side effects:
http://www.wsw.com/webcast/rrshq10/oxgn/3__Slide16.JPG
OXGN SAFETY:Lazard pres.

Seasoned and creditentialled Mgt Team under Dr. Richard Chin who guided two of Genentechs current blockbusters: Avastin & Lucentis. In his 3rd month as CEO downsized co 33% and focused strategy of timely executions.

Poised for Success is OXGN's Mantra.

$4+mln of open mkt purchases by mgt team! $65K during Aug 5-10 by newest director Fickling.

Indeed rare to find a $100 mln Mkt Cap. oncology play IN Phase THREE!

Recs

2
Member Avatar jwfoster (28.77) Submitted: 5/5/2007 10:34:23 PM : Outperform Start Price: $1,137.60 OXGN Score: -139.78

I am not smart enough to figure out which drugs will be good or bad. What will pass phase III trials, etc. But, what I do know is that when a biotech stock has tons of insiders who know the drug business buying up shares like crazy and have a lung cancer product that they can charge whatever they would want, it is worthy of buying.

This is not just a caps pick but, one of my larger personal holdings.

Recs

0
Member Avatar oj1480 (< 20) Submitted: 2/5/2007 10:50:03 AM : Outperform Start Price: $1,063.20 OXGN Score: -143.89

i heard good news about this one.

Recs

0
Member Avatar TechnicalTommy (73.71) Submitted: 1/17/2007 4:29:07 AM : Outperform Start Price: $1,130.40 OXGN Score: -145.76

Favorable news from pipeline in December. Things have finally settled down now.

Recs

0
Member Avatar alyssakh (< 20) Submitted: 11/25/2006 9:48:23 PM : Outperform Start Price: $1,080.00 OXGN Score: -148.51

Clinical trials almost done.

Recs

0
Member Avatar guy1818181818 (< 20) Submitted: 9/25/2006 8:17:30 PM : Outperform Start Price: $950.40 OXGN Score: -156.31

5x potential

Results 1 - 16 of 16

Featured Broker Partners


Advertisement